Form 4: Akari Director Boosts Stake via Warrants & Note Exchange

Akari Therapeutics director and 10% owner Hoyoung Huh increased beneficial ownership through a private placement of warrants and an exchange of a promissory note for additional warrants.

Summary

• Hoyoung Huh, a Director and 10% Owner of Akari Therapeutics Plc, acquired derivative securities on December 16, 2025.
• The acquisition included 618,658 unregistered pre-funded warrants (PIPE PFWs) and 618,658 accompanying Series G Warrants in a private placement. The combined purchase price was $0.4041 per PIPE PFW and Series G Warrant.
• Additionally, in exchange for an outstanding unsecured promissory note, Hoyoung Huh received 3,093,293 unregistered pre-funded warrants (Note Exchange Unregistered Pre-Funded Warrants) at a purchase price of $0.4041 per warrant, and 3,093,293 unregistered warrants (Note Exchange Unregistered Warrants).
• Each American Depositary Share (ADS) represents 2,000 Ordinary Shares.
• The Series G Warrants and Note Exchange Unregistered Warrants have an exercise price of $0.3883 per ADS and a five-year term from shareholder approval.
• The PIPE PFWs and Note Exchange Unregistered Pre-Funded Warrants have a conversion/exercise price of $0.00001 per ADS and remain exercisable until fully exercised.
• All warrants and pre-funded warrants are exercisable upon shareholder approval.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to increased insider ownership and debt reduction through the note exchange. However, the contingent nature of warrant exercisability on shareholder approval and the potential for future dilution introduce elements of uncertainty and risk, preventing a higher score.

Positives

• Increased beneficial ownership by a director and 10% owner, signaling confidence in the company's future.
• The note cancellation and exchange agreement reduces the company's debt burden by converting a promissory note into equity-linked instruments.
• The private placement provides capital to the company.

Negatives

• The exercisability of all warrants and pre-funded warrants is contingent on shareholder approval, introducing uncertainty.
• Potential for future dilution of existing shareholders upon exercise of the significant number of warrants and pre-funded warrants.

Risks

• Shareholder Approval Risk: The exercisability of all acquired warrants and pre-funded warrants is subject to shareholder approval, which may not be obtained.
• Dilution Risk: Future exercise of the significant number of warrants and pre-funded warrants could lead to substantial dilution for existing shareholders.
• Market Price Volatility: The value of the warrants and pre-funded warrants, and the incentive to exercise them, is dependent on the future market price of Akari Therapeutics ADSs.

Future Outlook

The future exercisability of the acquired warrants and pre-funded warrants is contingent upon obtaining shareholder approval. Once approved, the Series G Warrants and Note Exchange Unregistered Warrants will have a five-year term, while the pre-funded warrants will remain exercisable until fully exercised.

Industry Context

Insider transactions, such as those reported in a Form 4, are common across all industries. For smaller biotechnology companies like Akari Therapeutics, private placements and debt-to-equity conversions via warrants are frequently utilized mechanisms for capital raising and balance sheet management, especially when traditional equity financing might be challenging or highly dilutive at current market valuations.

Corporate Governance

Related Party Transactions

• The note cancellation and exchange agreement involved the Issuer and Hoyoung Huh, a Director and 10% Owner, converting an unsecured promissory note held by him into warrants and pre-funded warrants.
• The private placement transaction also involved Hoyoung Huh, a related party, acquiring warrants and pre-funded warrants.

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of the warrants and pre-funded warrants. Will need to vote on the approval of warrant exercisability.
• Company: Benefits from debt reduction through the note exchange and capital infusion from the private placement.
• Creditors: The conversion of a promissory note reduces the company's outstanding debt.

Next Steps

• The company needs to obtain shareholder approval for the exercisability of the Series G Warrants, Note Exchange Unregistered Warrants, PIPE PFWs, and Note Exchange Unregistered Pre-Funded Warrants.

Key Dates

Keywords

Akari Therapeutics, AKTX, Form 4, insider transaction, beneficial ownership, warrants, pre-funded warrants, private placement, debt-to-equity, director, 10% owner, equity financing, SEC filing, corporate governance